Literature DB >> 18480841

Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA.

Xiao Ni1, Heather M Richmond2, Xingsheng M Liao3, William K Decker4, Lisa H Shiue2, Elizabeth J Shpall4, Madeleine Duvic2.   

Abstract

Sézary syndrome (SzS), the leukemic variant of cutaneous T-cell lymphomas, is incurable. Dendritic cells (DCs) transfected with tumor mRNA can stimulate antitumor immunity in certain cancer patients. In this study, we determined whether mRNAs from Sézary cells could be used for loading DCs and stimulating antitumor immunity. Autologous DCs were generated from monocytes of the peripheral blood from 10 patients with SzS. Total RNA was extracted from Sézary cells and amplified by T7 in vitro transcription. The induction of antitumor IFN-gamma and granzyme B (GrB)-producing cytotoxic T lymphocytes (CTL) by RNA-transfected DCs was determined by ELISPOT assays. We found that IFN-gamma was required for IL-12p70 production by monocyte-derived DCs from SzS. The oncogenic transcription factor Twist and the tyrosine kinase receptor EphA4 were expressed in total RNA from Sézary cells and the paired amplified mRNAs. RNA-transfected DCs induced antitumor IFN-gamma-producing CTLs in 7 of 10 subjects and GrB-producing CTLs in 6 of 9 subjects. Both CD3+CD8+ T cells and CD4+CD25+ T cells were expanded without induction of regulatory T cells. These data support the concept of using tumor mRNA for a vaccine strategy that requires small amounts of tumor cells without need for specific antigens in patients with SzS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480841     DOI: 10.1038/jid.2008.125

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.

Authors:  Xiao Ni; Timothy Langridge; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2015-03-24       Impact factor: 8.110

Review 2.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.

Authors:  Meghali Goswami; Madeleine Duvic; Alexis Dougherty; Xiao Ni
Journal:  J Cutan Pathol       Date:  2012-05       Impact factor: 1.587

4.  The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.

Authors:  Lisa H Shiue; Jacob Couturier; Dorothy E Lewis; Caimiao Wei; Xiao Ni; Madeleine Duvic
Journal:  Photodermatol Photoimmunol Photomed       Date:  2015-03-28       Impact factor: 3.135

Review 5.  Active immunotherapy: current state of the art in vaccine approaches for NHL.

Authors:  M Lia Palomba
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

6.  Allogeneic mRNA-based electrotransfection of autologous dendritic cells and specific antitumor effects against osteosarcoma in rats.

Authors:  Zhe Yu; Jixian Qian; Jiachang Wu; Jie Gao; Minghua Zhang
Journal:  Med Oncol       Date:  2012-07-28       Impact factor: 3.064

Review 7.  Lessons learned from gene expression profiling of cutaneous T-cell lymphoma.

Authors:  B O Dulmage; L J Geskin
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

8.  Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease.

Authors:  Lisa H Shiue; Amin M Alousi; Caimiao Wei; Chitra M Hosing; Madeleine Duvic; Xiao Ni
Journal:  J Invest Dermatol       Date:  2013-03-21       Impact factor: 8.551

Review 9.  The emerging role of Twist proteins in hematopoietic cells and hematological malignancies.

Authors:  N Merindol; A Riquet; V Szablewski; J-F Eliaou; A Puisieux; N Bonnefoy
Journal:  Blood Cancer J       Date:  2014-04-25       Impact factor: 11.037

Review 10.  Lymphoma Immunotherapy: Current Status.

Authors:  Roberta Zappasodi; Filippo de Braud; Massimo Di Nicola
Journal:  Front Immunol       Date:  2015-09-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.